Patrick W McGarrah

Dr. Patrick W McGarrah

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2018 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
ZGZhijun Guo
Zhijun Guo
VJVeronica Johnson
Veronica Johnson
JBJaime Barrera
Jaime Barrera
MPMariel Porras
Mariel Porras
DHDiego Hinojosa
Diego Hinojosa
DPDavid A Potter
David A Potter

1 August 2020 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
PMPatrick W McGarrah
Patrick W McGarrah
GWGustavo F.M. Westin
Gustavo F.M. Westin
THTimothy J. Hobday
Timothy J. Hobday
JSJoseph A. Scales
Joseph A. Scales
JIJohann P. Ingimarsson
Johann P. Ingimarsson
Thorvardur HalfdanarsonThorvardur Halfdanarson
Thorvardur Halfdanarson

1 April 2020 in Pancreas
Verified
Journal Article
Closed access
PMPatrick W McGarrah
Patrick W McGarrah
KLKonstantinos Leventakos
Konstantinos Leventakos
THTimothy J. Hobday
Timothy J. Hobday
JMJulian R. Molina
Julian R. Molina
HFHeidi D. PharmD Finnes
Heidi D. PharmD Finnes
Thorvardur HalfdanarsonThorvardur Halfdanarson
Thorvardur Halfdanarson
Objectives: A platinum/etoposide doublet is standard first-line therapy for poorly differentiated neuroendocrine carcinoma (PD NEC); however, evidence to guide treatment beyond first-line regimens is lacking. This study aimed to evaluate the efficacy of second-line regimens in PD NEC. Methods: We performed a retrospective analysis of patients treated with second-line chemotherapy for PD NEC. Inclusion criteria were previous first-line therapy with platinum/etoposide, extrapulmonary PD NEC, and follow-up data. The primary end points were overall survival (OS) and progression-free survival (PFS) after second-line therapy. Secondary end points included OS and PFS from first-line therapy. Results: Sixty-four patients were included. The median OS from initiation of second-line therapy was 6.2 months (95% confidence interval [CI], 4.9–8.9). The median PFS was 2.3 months (95% CI, 2.0–3.2). No second-line regimen showed a statistically significant difference in OS or PFS. There was a significant increase in OS for cisplatin first-line regimens compared with carboplatin (17.0 months [95% CI, 12.5–22.6] vs 11.7 months [95% CI, 8.0–14.0]). Conclusions: The efficacy of current second-line therapy in PD NEC is poor. No second-line regimen showed statistically significant superiority. Cisplatin was associated with longer OS regardless of second-line regimen or age. However, unmeasured confounders such as performance status or comorbidities may explain this effect.

18 August 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
LZLei Zhang
Lei Zhang
CKCherkaouia Kibaly
Cherkaouia Kibaly
YWYu‐Jun Wang
Yu‐Jun Wang
CXChi Xu
Chi Xu
KSKyu Young Song
Kyu Young Song
PLPing‐Yee Law
Ping‐Yee Law
Opiate withdrawal/negative reinforcement has been implicated as one of the mechanisms for the progression from impulsive to compulsive drug use. Increase in the intracellular cAMP level and protein kinase A (PKA) activities within the neurocircuitry of addiction has been a leading hypothesis for opiate addiction. This increase requires the phosphorylation of μ‐opioid receptor (MOR) at Tyr336 by Src after prolonged opiate treatment in vitro. Here, we report that the Src‐mediated MOR phosphorylation at Tyr336 is a prerequisite for opiate withdrawal in mice. We observed the recruitment of Src in the vicinity of MOR and an increase in phosphorylated Tyr336 (pY336) levels during naloxone‐precipitated withdrawal. The intracerebroventricular or stereotaxic injection of a Src inhibitor (AZD0530), or Src shRNA viruses attenuated pY336 levels, and several somatic withdrawal signs. This was also observed in Fyn−/− mice. The stereotaxic injection of wild‐type MOR, but not mutant (Y336F) MOR, lentiviruses into the locus coeruleus of MOR−/− mice restored somatic withdrawal jumping. Regulating pY336 levels during withdrawal might be a future target for drug development to prevent opiate addictive behaviors. Synopsis The μ‐opioid receptor (MOR) non‐canonical signaling pathway involves its phosphorylation at Tyr336 by Src kinase within the MOR signal complex. The focal event of MORY336 phosphorylation may be the key for adenylyl cyclase superactivation during the withdrawal/negative stage of opiate addiction. The phosphorylation levels of MORY336 and SrcY416 increased during naloxone‐precipitated withdrawal in wild‐type mice. The intracerebroventricular or stereotaxic injection of a Src inhibitor (AZD0530), or Src shRNA viruses reduced pMORY336 and pSrcY416 levels, and several somatic withdrawal signs. Increases of pMORY336 levels as well as some somatic withdrawal signs after naloxone‐precipitated withdrawal were not observed in Fyn−/− mice. The stereotaxic injection of wild‐type MOR lentiviruses into the locus coeruleus of MOR−/− mice restored somatic withdrawal jumping and wet dog shaking. The stereotaxic injection of the phosphorylation‐deficient mutant (Y336F) MOR, in which the mutation of Tyr336 to Phe blocks Src‐mediated phosphorylation, attenuated naloxone‐precipitated withdrawal.

1 February 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DCDavid Chan
David Chan
EBEmily K. Bergsland
Emily K. Bergsland
JCJennifer A. Chan
Jennifer A. Chan
RGRujuta Gadgil
Rujuta Gadgil
Thorvardur HalfdanarsonThorvardur Halfdanarson
Thorvardur Halfdanarson
SSSimron Singh
Simron Singh
321 Background: G3 NENs are aggressive, and optimal systemic treatment is unclear. Temozolomide (TEM)-based regimens have been used to treat grade 1-2 NETs, but their efficacy in G3 NENs (Ki-67 > 20%) remains undetermined. Aims: To assess the clinical efficacy of TEM-containing regimens in advanced grade III gastroenteropancreatic NENs (GEPNENs). Methods: A multicentre retrospective review (2008-2017) of patients with metastatic/unresectable G3 GEPNENs who received a TEM-containing regimen. The primary endpoint was time to treatment failure (TTF). Radiologic response was extracted from local reports without formal RECIST criteria. Results: 118 patients in six centers were included (median age 55, 65% male, 15% functional, 75% pancreatic NEN). 57% were well-differentiated, 35% poorly-differentiated, and 18% unknown based on local pathology reports. The regimen used was CAPTEM in 93% and TEM in 7%. Best radiological responses were: complete response (1%), partial response (39%), stable disease (22%), progressive disease (31%), unknown (7%) not by RECIST. Median TTF was 150 days and median overall survival (OS) 18.0 months. Fifteen patients (14%) required dose reductions/discontinuation due to adverse events. TTF was shorter for patients on TEM alone (p = 0.02, Table 1). Well-differentiated NENs had better response rate (52% vs 26%, p = 0.02) and overall survival (30.1 vs 12.0 mo, p = 0.008) compared to poorly-differentiated NEN. Conclusions: This is the largest TEM treatment series in G3 NEN, involving collaboration of several major North American NET centers. 40% of patients showed some degree of response, and treatment was generally well-tolerated. TEM-based regimens should be considered a viable treatment option in this setting. Prospective confirmatory trials (such as EA2142) may face difficulties in accrual due to disease rarity. [Table: see text]

1 February 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PMPatrick W McGarrah
Patrick W McGarrah
THTimothy J. Hobday
Timothy J. Hobday
JSJason Scott Starr
Jason Scott Starr
AKAyse T. Kendi
Ayse T. Kendi
RGRondell P. Graham
Rondell P. Graham
THThorvardur Ragnar Halfdanarson
Thorvardur Ragnar Halfdanarson
617 Background: Currently, there is no published data on the efficacy of SSAs for well-differentiated G3 NETs. Randomized trials have demonstrated a progression-free survival (PFS) benefit and limited tumor response for lower grade 1-2 NETs, but the optimal systemic therapy for metastatic/unresectable G3 NETs is unknown. We sought to evaluate the efficacy of SSAs in G3 NETs. Methods: We performed a retrospective analysis of Mayo Clinic patients treated with SSAs for metastatic/unresectable G3 NETs, querying data from 1992 - present. Inclusion criteria were: centrally reviewed pathology confirming well-differentiated morphology, G3 based on WHO classification, SSA monotherapy, and radiological data available to assess response. Patients who had prior lines of treatment were included as long they subsequently were treated with single-agent SSA. Poorly-differentiated tumors were excluded. The primary endpoint was PFS. Best overall response was determined by radiographic regression, stabilization, or progression of tumor size. Results: Ninety patient records were reviewed, with 14 meeting inclusion criteria (diagnosed 2014 – 2018). Median Ki-67 proliferative index was 25%. Two patients (14%) had a partial response to SSA therapy, five (36%) had stable disease, and seven (50%) had progressive disease. The estimated median PFS was 4.4 months (95% CI 2.9 – 24). Of the 7 patients with stable disease or partial response, the median time to progression was 8.7 months. Three patients had stable disease for greater than 9 months (24, 29 and 42 months, respectively). Overall survival was not estimable. There was no association of Ki-67 index with PFS based on a proportional hazards model. Conclusions: This is the first report on the efficacy of SSAs for G3 NETs. Although half of the patients in our series had at least stable disease, the PFS was modest at only 4.4 months. Given their favorable side-effect profile compared to cytotoxic chemotherapy, SSAs may present an attractive option to be further explored in a prospective fashion. We are presently updating this data by reassessing response using RECIST criteria.